Clinical trial
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic…
NCT00230282 · Steven E. Coutre, Other · Completed
Key facts
| NCT number | NCT00230282 |
|---|---|
| Title | Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia |
| Official title | A Multi-Center Phase 2 Efficacy and Pharmacokinetic Study Evaluating Fludarabine, Cyclophosphamide, and Subcutaneous Campath (FCCam, Alemtuzumab) for Previously Untreated B-Cell Chronic Lymphocytic Leukemia |
| Lead sponsor | Steven E. Coutre, Other |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, B-cell Leukemia, Chronic Leukemia, Chronic Lymphocytic Leukemia (CLL) |
| Intervention type | Drug |
| Interventions | Alemtuzumab, Fludarabine, Cytoxan |
| Enrollment | 25 |
| Start date | Jul 1, 2004 |
| Primary completion | Dec 1, 2010 |
| Completion | Oct 1, 2011 |
| First posted | Sep 30, 2005 |
| Last update posted | Oct 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: